Stockwinners Market Radar for November 30, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:22 EDT Alio announces departure of COO Doug Jones - Alio Gold has filed on SEDAR a National Instrument 43-101 compliant technical report titled "Independent Technical Report Mineral Resource Update for the Florida Canyon Gold Mine, Pershing County Nevada, USA" for the updated Florida Canyon Mineral Resource Estimate announced on October 18, 2018. The Mineral Reserve Estimate and Life of Mine Plan are nearing completion and are on track to be finalized by the end of the year. With the Technical Report completed and the Florida Canyon Mine fully integrated into the Company, Doug Jones, COO has left the company. Jones joined the company from Rye Patch Gold Corp. following its acquisition by the company in May 2018. Going forward, the General Managers at the Florida Canyon and San Francisco Mines will report directly to Greg McCunn, CEO. The company also announces that it has completed the previously announced sale of its non-core assets to Coeur Rochester, a wholly-owned subsidiary of Coeur Mining (CDE). Pursuant to the terms of the transaction, Alio Gold received an aggregate of 4,268,703 common shares of Coeur and is in the process of transferring all data and materials related to the assets to Coeur.

17:30 EDT Empery Asset Management reports 9.99% passive stake in Intellipharmaceutics

17:22 EDT Bain Capital lowers stake in Skyline to 8.9% from 12.0%

17:07 EDT Oaktree Holdings reports 7.06% passive stake in Bonanza Creek

17:03 EDT Ayrton Capital reports 4.99% passive stake in Heat Biologics

16:44 EDT Titan Machinery CEO sells 53,000 common shares - In a regulatory filing, Titan Machinery chairman and CEO David Joseph Meyer disclosed the sale of 53,000 common shares at a price of $18.56 per share.

16:42 EDT Sprouts Farmers Market's Boney acquires 88,500 common shares - In a regulatory filing Sprouts Farmers Market director Shon A. Boney disclosed the purchase of 88,500 common shares of the company at a price of $22.8266 per share.

16:31 EDT Sharing Economy International to delist from Nasdaq, move listing to OTC Markets - Sharing Economy International announced that on November 26, 2018, Sharing Economy International Inc. received a staff determination notice from The Nasdaq Stock Market informing the company that as a result of its failure to comply with Nasdaq's shareholder approval requirements set forth in Listing Rule 5635c, the staff had determined to deny the company's request for continued listed based on a plan of compliance submitted on October 26, 2018. In the determination notice, the staff expressed its concern that the plan of compliance did not represent a definitive plan evidencing the company's ability to comply with the Rule due to a portion of the shares issued in violation of the Rule having been sold in the market and the lack of signed commitments from other holders of shares issued in violation of the Rule to participate in a proposed exchange offer intended to remediate such issuances by virtue of a subsequent special meeting of stockholders to be held to approve them. Nasdaq further informed the company that, in accordance with Listing Rule 5101, unless the company requests an appeal of the staff's determination, the company's common stock will be suspended from trading on the Nasdaq Capital Market at the opening of business on December 5, 2018. The company has decided not to appeal the Nasdaq determination notice and is instead moving its stock listing to the OTC Markets. The company believes OTC Markets is more suitable to its capital and business needs at this time as it undergoes the transition of its business and pursues aggressive growth strategies in the coming years. Although SEII is moving its stock listing to a different market, the Company intends to continue to maintain high quality reporting and disclosure standards and will continue to improve its corporate governance. The company's common stock will be delisted from Nasdaq effective at the open of trading on December 5, 2018. The company expects that its common stock will begin trading on the OTC Markets under the symbol SEII beginning on December 5, 2018.

16:30 EDT Monmouth Real Estate acquires industrial building in Savannah, GA for $27.8M - Monmouth Real Estate Investment Corporation announced the acquisition of a new 126,520 square foot industrial building located at 505 Morgan Lakes Industrial Boulevard, Savannah, GA at a purchase price of $27,832,781. The property is net-leased for 10 years to FedEx Ground Packaging System, Inc., a Delaware corporation. The building is situated on approximately 29 acres.

16:18 EDT LCI Industries sees Smoker Craft acquisition 'immediately accretive to earnings' - "We are excited to add Smoker Craft's furniture manufacturing business to the LCI family. This is very similar to the furniture manufacturing operation that we purchased from Godfrey Marine in 2016, and that transition went extremely well," said Jason Lippert, LCI CEO. Continued Lippert, "This will be our fourth marine furniture acquisition in the last four years and as we continue to grow in the marine space, more opportunities continue to present themselves. This line of business has grown so significantly that earlier this year we opened a 700,000 square foot facility in Fort Wayne, Indiana to serve our marine customers. We anticipate that the Smoker Craft furniture manufacturing business will remain in New Paris while we transition the operation into the LCI family. I have the utmost confidence in Ryan Smith and his teams to ensure that there is a smooth manufacturing transition with Smoker Craft. We expect this acquisition to be immediately accretive to LCI's earnings."

16:16 EDT McKesson to relocate corporate headquarters to Las Colinas, Texas - McKesson Corporation announced the relocation of its corporate headquarters from San Francisco, California to Las Colinas, Texas, effective April 1, 2019, expanding upon its presence in the Dallas area. "We are excited to strengthen our presence in Texas and make Las Colinas our official global headquarters," said John H. Hammergren, chairman and chief executive officer, McKesson Corporation. "Governor Abbott and the Irving/Las Colinas community have provided tremendous support since we opened our Las Colinas campus last April. Making this move will improve efficiency, collaboration and cost-competitiveness, while providing an exceptional work environment for our employees." McKesson's Las Colinas campus is already a key hub for the company. Employees at the North Texas location perform vital functions for the company in areas such as operations, information technology, finance and accounting, marketing and sales, administration and support, purchasing, and project management. As previously announced on April 25, 2018, McKesson launched a multi-year strategic growth initiative, inclusive of plans to optimize the company's operating and cost structures. The company expects these initiatives and actions will generate approximately $300M-$400M in annual pre-tax gross savings that will be substantially realized by the end of Fiscal 2021.

16:13 EDT Hecla Mining files to sell 865,703 shares of common stock for holders

16:07 EDT RadiSys announces CFIUS clearance regarding acquisition by Reliance Industries - Radisys announced that the Committee on Foreign Investment in the United States completed its review of the planned acquisition of the company by Reliance Industries. CFIUS clearance was the final governmental approval condition to closing the merger. With shareholder approval previously received on September 5, 2018, subject to the satisfaction or waiver of the remaining customary closing conditions, the parties expect to consummate the merger on December 7, 2018 or on such other date as the parties mutually agree. Upon the completion of the proposed transaction, Radisys shareholders will be entitled to receive $1.72 in cash per share, subject to the terms of the definitive merger agreement, and Radisys' common stock will no longer be publicly traded and will be delisted from the NASDAQ Global Select Market.

16:06 EDT Ocular Therapeutix trading halted, news pending

16:03 EDT United Natural Foods announces sale of SUPERVALU'S Hornbacher's stores - United Natural Foods announced that its newly acquired subsidiary, SUPERVALU, has entered into a definitive agreement whereby Coborn's will acquire seven Hornbacher's locations, as well as Hornbacher's newest store currently under development in West Fargo, N.D. The transaction is currently expected to close before Dec. 25, 2018, subject to customary closing conditions. As part of the sale, Coborn's plans to retain the Hornbacher's name and will enter into a long-term agreement for SUPERVALU to serve as the primary supplier of the Hornbacher's locations. As well, SUPERVALU will enter into an expanded supply relationship with Coborn's. Both of these supply agreements will include minimum purchase requirements. The Hornbacher's store in Grand Forks, N.D. is not included in the sale to Coborn's and will close. Liquidation will begin at the store on Monday, Dec. 3 and will close as the inventory liquidation is complete.

16:01 EDT Boeing delivers first 737 MAX airplane to Fiji Airways - Boeing delivered the first 737 MAX for Fiji Airways, which plans to use the fuel-efficient, longer-range version of the popular 737 jet to expand and modernize its single-aisle fleet. Fiji Airways plans to take delivery of five MAX 8 airplanes, which will build on the success of its fleet of Next-Generations 737s. In addition to modernizing its fleet, Fiji Airways will use Boeing Global Services to enhance its operations. These services include Airplane Health Management, which generates real-time, predictive service alerts, and Software Distribution Tools, which empowers airlines to securely manage digital ground-based data and efficiently manage software parts.

15:41 EDT Context BH Capital reports roughly 5.4% passive stake in Hamilton Bancorp

15:04 EDT Alaska Air temporarily suspending operations in Anchorage due to earthquake - Alaska Airlines' official corporate account tweeted: "Due to a significant earthquake in Anchorage, Alaska, we are temporarily suspending operations at the airport until at least 12:30pm Pacific. We will keep you updated here as well as on the Alaska Airlines Blog." Reference Link

14:48 EDT Laureate Education says DOJ closed inquiry into possible FCPA violations - In a regulatory filing last night, Laureate Education disclosed that on November 21, external counsel for the company received a letter from the U.S. Department of Justice stating that the DOJ had closed its inquiry into possible violations of the U.S. Foreign Corrupt Practices Act. "In the letter, the DOJ acknowledged our voluntary disclosure and full cooperation in its investigation, and the remediation that we have undertaken. The Company previously had received a letter from the Division of Enforcement of the Securities and Exchange Commission stating that it had concluded its investigation as to the Company with respect to such matters and did not intend to recommend an enforcement action against the Company by the SEC. As previously disclosed, during the fourth quarter of 2014, we discovered irregularities with respect to a donation by our network institution in Turkey, Istanbul Bilgi University, to a charitable foundation. In June 2016, the Audit Committee of our Board of Directors initiated an internal investigation into this matter with the assistance of external counsel. We voluntarily disclosed the investigation and facts related to the donation to the DOJ and the SEC, and the Company fully cooperated with those agencies in their subsequent inquiry and investigation relating to this matter," the company stated in the filing. In afternoon trading, Laureate Education shares are down 39c, or 2.6%, to $14.57.

14:00 EDT Gaming Partners announces special cash dividend of 12c share - Gaming Partners International announced that its board has authorized a special cash dividend of 12c per issued and outstanding share of common stock to be paid no later than December 21, 2018 to stockholders of record as of December 10.

13:19 EDT Atlas Air 'commends' U.S.-UK air services agreement - The company said, "Atlas Air Worldwide Holdings congratulates and thanks the United States government for reaching an open skies aviation agreement with the United Kingdom, to become effective when the air services agreement between the United States and Member States of the European Union ceases to apply to the United Kingdom following Brexit. The U.S.-UK agreement will ensure post-Brexit continuation of the market-driven aviation environment needed to facilitate continuing growth of U.S. jobs and the U.S. economy. 'We are extremely gratified that the United States continues to pursue its well-tested open skies aviation policy,' said CEO William Flynn. 'When it takes effect, the U.S.-UK air services agreement will improve the global scheduling options for our airline subsidiaries by allowing them to exercise seventh-freedom cargo rights to and from the United Kingdom.'"

13:01 EDT Ameresco acquires TerraNavigator, financial terms not disclosed - Ameresco announced that it has acquired TerraNavigator, LLC, a California-based firm that specializes in the origination and development of solar assets on environmentally-impacted sites throughout the country. With this acquisition, Ameresco will expand its pipeline of potential renewable energy projects with a focus on converting these project opportunities into operating assets that the company will own and operate. As part of the transaction, Ruben Fontes, formerly CEO of TerraNavigator, has joined Ameresco as Senior Vice President, Large Scale Distributed Energy Resources.

12:31 EDT Cloverdale Capital reports 5.03% passive stake in Bridgepoint Education

12:00 EDT Callaway Golf falls -16.2% - Callaway Golf is down -16.2%, or -$3.06 to $15.85.

12:00 EDT Vivint Solar falls -21.1% - Vivint Solar is down -21.1%, or -$1.48 to $5.52.

12:00 EDT EQGP Holdings rises 17.5% - EQGP Holdings is up 17.5%, or $2.98 to $20.00.

11:40 EDT Daimler, SKF announce settlement agreement with respect to legal dispute - SKF and Daimler AG have entered into a settlement agreement with respect to their dispute before the regional court Nuremberg-Fuerth in Germany regarding damage claims resulting from the European Commission's decision on the violation of European competition rules with respect to automotive bearings. Daimler initiated this lawsuit against SKF GmbH in June 2017. The parties agreed to treat details of the settlement as confidential. This settlement is not an admission of liability for damages, but is made in order to enable SKF and Daimler to continue their long-standing commercial relationship. The settlement will have an insignificant impact on the financial position of the Group.

11:04 EDT Fitch upgrades Fiat Chrysler to investment grade 'BBB-' rating - Fitch Ratings announced that it has upgraded Fiat Chrysler Automobiles' ratings, including the Long-Term Issuer Default Rating, to 'BBB-' from 'BB'. The Outlook on the Long-Term IDR is Stable. "The upgrade reflects the continuous strengthening of FCA's financial profile and our expectation that this improvement is sustainable despite a potential cyclical weakening of new vehicle sales in some of the key markets where FCA is active. In particular, we expect free cash flow to remain on average above 1.5% in the foreseeable future and funds from operations adjusted net leverage to decline further to around breakeven by end-2020. FCA's credit profile has also been supported by the disposal of Magneti Marelli, FCA's main components business, which is expected to be completed in 2019. This will further lower the group's net indebtedness and improve financial flexibility. The upgrade also reflects FCA's solid business profile, consistent with a low investment-grade rating," Fitch stated.

10:40 EDT Sanderson Farms to discontinue use of certain antibiotics in live poultry ops - Sanderson Farms announced that it will discontinue by March 1, 2019, using antibiotics considered medically important for humans for disease prevention in its live poultry operations. The change follows the completion of an independent study the Company commissioned earlier this year on its antibiotics program for its live operations. As part of its ongoing animal welfare and antibiotic stewardship efforts, the Company commissioned an advisory board of scientific experts in poultry production, livestock management, and antibiotic use in veterinary and human medicine to study and report on the Company's use of antibiotics in its live poultry production operations. The advisory board found no misuse of antibiotics at Sanderson Farms or other deficiencies in its program. Instead, the advisory board found that compared to the rest of the industry, the Company's broiler chickens "have better than average health," and that "current management practices, including their use of antibiotics, are effective to preserve the health and life of chicks and birds." The advisory board also believes the number of broiler chickens treated with antibiotics for disease at Sanderson Farms in 2017 "is low relative to conventional operations of comparable size." Commenting on the advisory board's report, CEO Joe Sanderson said, "We are grateful for the work of the independent scientists who served on the advisory board, and we value their findings. As a result of their report, we have determined to discontinue by March 1, 2019, the use of gentamicin and virginiamycin for prevention of disease in our live operations. These are the only two antibiotics considered medically important for humans that we currently use for prevention purposes. Our live production team, including our team of veterinarians, is prepared to ensure this change has as little impact as possible on the health and welfare of our birds and environmental resources."

10:02 EDT Pfizer signs licensing agreements with AbbVie resolving IP matters - Pfizer (PFE) announced that it has signed licensing agreements with AbbVie (ABBV), resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under the terms of the agreements, AbbVie grants Pfizer a non-exclusive patent license for the use and sale of Pfizer's proposed adalimumab biosimilar for many countries around the world. Pfizer may launch its adalimumab biosimilar upon approval by the European Medicines Agency in Europe. In the United States, the license period will begin on November 20, 2023. All litigation pending between the parties will be withdrawn. The financial details of the agreements are confidential.

10:00 EDT Vivint Solar falls -18.1% - Vivint Solar is down -18.1%, or -$1.27 to $5.73.

10:00 EDT Britannia Bulk rises 8.1% - Britannia Bulk is up 8.1%, or $1.07 to $14.36.

10:00 EDT EQGP Holdings rises 17.7% - EQGP Holdings is up 17.7%, or $3.00 to $20.02.

09:50 EDT FRONTEO Inc (ADS) trading resumes

09:47 EDT Cosan rises 10.6% - Cosan is up 10.6%, or 86c to $8.95.

09:45 EDT FRONTEO Inc (ADS) trading halted, volatility trading pause

09:11 EDT Zagg acquires Gear4 for $40M - Zagg announced it has acquired Gear4 from STRAX AB $40M, the equivalent of 1X 2018 projected sales. Accounting for 23% market share in the U.K. and having experienced significant growth in North America this year, Gear4's range of impact absorbing smartphone cases covers all leading handsets. Gear4's cases exclusively feature D3O technology. With more than 1.9B smartphones predicted to ship during 2018, the Gear4 acquisition complements the ZAGG product portfolio and provides credible access of a growing brand to a large category driven by demand for mobile devices globally. ZAGG Inc will acquire the Gear4 corporate headquarters located in Maidenhead, England, and retain the services of its talented employees located in the U.S., Canada, the U.K. and Hong Kong.

09:05 EDT Clementia Pharmaceuticals announces CCO Eric Grinstead departs - Clementia Pharmaceuticals announced the departure of Eric Grinstead as the company's CCO effective November 30. The company has initiated a search process for a new CCO, who is expected to have significant product launch and market access experience. Steve Forte, CFO, will assume responsibility for the company's ongoing pre-commercial efforts in the interim.

08:58 EDT Keryx announces Glass Lewis recommendation for Akebia merger - Keryx (KERX) announced that independent proxy advisory firm Glass Lewis recommends Keryx stockholders vote "FOR" the proposals relating to the proposed merger with Akebia (AKBA) at the special meeting of Keryx stockholders to be held on December 11. In recommending that Keryx stockholders vote "FOR" the merger and the related proposals, Glass Lewis recognized in its report that "the fundamental underpinnings of the proposed arrangement are both straightforward and sound" and that there is "a compelling case to combine the two firms." The Keryx board unanimously recommends that Keryx stockholders vote "FOR" the proposals relating to the proposed merger. Additionally, Keryx's largest stockholder, The Baupost Group, has entered into a voting agreement in support of the transaction.

08:57 EDT Akebia says Glass Lewis recommends shareholders vote for proposed Keryx merger - Akebia Therapeutics (AKBA) announced that independent proxy advisory firm, Glass Lewis & Co., joins Institutional Shareholder Services in recommending that Akebia shareholders vote "FOR" the shareholder proposals relating to the Company's proposed merger with Keryx Biopharmaceuticals (KERX). In its report dated November 29, 2018, Glass Lewis stated:"Based on the foregoing factors and the unanimous support of the board, we believe there is sufficient procedural, strategic and financial cause for investor support here. Accordingly, we recommend shareholders vote FOR this proposal...Speaking first to strategic fit, we believe the fundamental underpinnings of the proposed arrangement are both straightforward and sound...Akebia has, in our view, reasonably elected to partner with another renal disease-focused enterprise with existing sales and marketing infrastructure and an approved treatment." The merger of Akebia and Keryx is subject to the satisfaction of various closing conditions, including approval by shareholders of both companies. The special meeting of Akebia shareholders to vote on matters relating to the proposed merger has been scheduled for December 11, 2018. Holders of record of Akebia common stock as of 5:00 p.m. Eastern Time on October 22, 2018, will be entitled to vote at the special meeting. The Akebia Board of Directors strongly urges Akebia shareholders to vote "FOR" the Akebia proposals set forth in the definitive proxy statement, including "FOR" the proposal to issue shares of Akebia common stock to Keryx shareholders in relation to the proposed merger.

08:43 EDT Orgenesis subsidiary expands production, doubles capacity - Orgenesis announced that its subsidiary, Masthercell Globa has launched a new production wing of 600 square meters at its Belgium site in the presence of Belgium's Public Health and Social Affairs Minister, Maggie De Block, and the Minister-President of Wallonia, Willy Borsus. Masthercell is also backed by Great Point Partners. The expansion of the current Belgium plant provides Masthercell five additional, late stage and commercial ready clean rooms. This new wing has been designed with an agility-by-design approach. This allows clients to adapt clinical versus commercial segregation and clean room surface optimization for both isolation of certain parts of the facility and doubling of clean room size. Each clean room of the new production wing is 30 square meters with independent HVAC systems to ensure full autonomy and independent maintenance management. The new wing also brings additional capabilities, including two development laboratories, one quality control laboratory and additional warehouse capabilities.

08:39 EDT Sellas Life Sciences to present nelipepimut-S, trastuzumab trial data at SABCS - Sellas Life Sciences announced that further correlative data from the Phase 2b trial of nelipepimut-S in combination with trastuzumab for the treatment of women with triple-negative breast cancer, or TNBC, will be presented at the 2018 San Antonio Breast Cancer Symposium, or SABCS. The data will include efficacy results from analysis of key predefined subgroups and the difference in the patterns of disease relapse between the active versus the control arms.

08:34 EDT Great Panther Silver says 'progressing well' towards Beadell acquisition - Great Panther Silver provides the following update with respect to its proposed acquisition of Beadell Resources. As noted in the press release dated September 23, 2018 announcing Great Panther's friendly acquisition of Beadell, the closing of the acquisition is conditional upon certain arrangements relating to Beadell's outstanding $10M convertible debentures. "We are advancing through the regulatory process in Australia and progressing well towards the completion of our acquisition of Beadell and expect respective meetings seeking shareholder approvals to take place early in 2019", stated James Bannantine, President and CEO. "This latest announcement is an important next step, as we are confirming our intention to offer to purchase the Convertible Debentures immediately after Closing and amend the existing terms as required in the event of an acquisition. Should the current debenture holders choose to continue to hold the Convertible Debentures, they will benefit from an improved credit profile. Otherwise, Great Panther has the balance sheet to purchase the Convertible Debentures and is also considering options to refinance." The Acquisition will constitute a change of control, as defined in the indenture governing the Convertible Debentures of Beadell. In accordance with the terms of the Debenture Indenture, upon the occurrence of a Change of Control, Beadell is required to make an offer to purchase all Convertible Debentures at a price per Convertible Debenture equal to 105% of the principal amount, plus accrued and unpaid interest. In connection with the Acquisition, it is expected that Beadell will make the Change of Control Purchase Offer under Great Panther's direction. In connection with the Acquisition, it is also anticipated that Great Panther will enter into an amended and restated or supplemental Debenture Indenture pursuant to which Great Panther will expressly assume the obligations of Beadell under the Debenture Indenture and the holders of Convertible Debentures will be entitled to receive Great Panther Shares on the conversion thereof, to the extent that any Convertible Debentures remain outstanding after the Change of Control Purchase Offer. Additional amendments may be made in connection with the entering into of such amended and restated or supplemental indenture if mutual agreement between Great Panther and the holders of the Convertible Debentures can be secured and if any Convertible Debentures remain outstanding after the Change of Control Purchase Offer.

08:30 EDT Influential Amazon investor confident in Prime Health roll-out, CNBC says - Speaking at the Forbes Healthcare conference this week venture capital star John Doerr said "Amazon is among the best-positioned companies to take information its learned from customers and use it to their benefit," according to a CNBC story. Doerr is confident Amazon CEO Jeff Bezos will "roll out an offering for medical and health products that resembles Amazon Prime, which has over 100M users," added CNBC.

08:22 EDT Fate Therapeutics announces FDA acceptance of FT500 IND - Fate Therapeutics announced that the FDA has allowed its investigational new drug, or IND, Application for FT500, the company's universal, off-the-shelf natural killer, or NK, cell product candidate derived from a clonal master induced pluripotent stem cell, or iPSC, line. The clinical trial of FT500 is expected to be the first-ever clinical investigation in the U.S. of an iPSC-derived cell product. The company plans to initiate first-in-human clinical testing of FT500 in combination with checkpoint inhibitor therapy for the treatment of advanced solid tumors. This study is expected to evaluate the safety and tolerability of multiple doses of FT500, in multiple dosing cycles with nivolumab, pembrolizumab or atezolizumab, in subjects that have progressed or failed on checkpoint inhibitor therapy.

08:12 EDT Cosan commences tender offer to repurchase up to $100M of Class A shares - Cosan announced that it has commenced a tender offer to purchase up to $100M of its Class A common shares, or the shares, at (i) prices specified by the tendering shareholders of not greater than U.S.$9.30 nor less than U.S.$8.88 per share or (ii) at the purchase price determined in accordance with the tender offer. The NYSE closing price of the shares on November 29, 2018, the last full trading day before the commencement of the tender offer, was U.S.$8.09 per share. When the tender offer expires, Cosan will determine the lowest price per share within the range of prices specified above that will enable it to purchase the maximum number of shares having an aggregate purchase price not exceeding $100M. All shares purchased in the tender offer will be purchased at the same price. All shares tendered at prices higher than the purchase price will be promptly returned to shareholders. If the tender offer is fully subscribed, Cosan would repurchase between 7.2% and 7.6% of its issued and outstanding shares as of November 30, 2018, depending on the purchase price payable in the tender offer. The tender offer will expire at 11:59 p.m., New York City time, on December 28, 2018, unless extended by Cosan.

08:09 EDT Equitrans Midstream to acquire EQGP Holdings for $20.00 per unit in cash - Equitrans Midstream Corporation (ETRN) announced that it has entered into definitive purchase agreements with certain unitholders of EQGP Holdings (EQGP) to acquire limited partner interests in EQGP for $20.00 per unit in cash, which is a 17.5% premium to the EQGP closing market price as of November 29, 2018. The Private Purchases are expected to close on or about December 31, 2018, after which ETRN and its affiliates will own more than 95% of the outstanding EQGP Common Units. Upon closing of the Private Purchases, ETRN intends to exercise the Limited Call Right under EQGP's partnership agreement to acquire all remaining EQGP Common Units not then owned by ETRN and its affiliates. If the Limited Call Right is exercised, the remaining holders of EQGP Common Units will receive at least the same cash price per unit that will be paid in the Private Purchases. The Limited Call Right is expected to close in January 2019 and will be a taxable transaction for EQGP unitholders. ETRN intends to use the cash proceeds from a newly issued Term Loan B to finance the Private Purchases and the purchases pursuant to the Limited Call Right. ETRN has secured committed financing in support of these purchases. ETRN also announced that it has made a proposal to EQM Midstream Partners (EQM) for the exchange of its incentive distribution rights and the economic general partner interest in EQM for 95 million units in EQM and a non-economic general partner interest in EQM, subject to the closing of the Private Purchases and completion of the Limited Call Right. ETRN expects that a portion of the units received will be in the form of Payment-In-Kind Units. The PIK Units would receive distributions in the form of additional PIK Units and would convert on a one-to-one basis into common units representing limited partner interests in EQM at a date to be determined. Final terms of the Proposed IDR Transaction are subject to negotiation with the board of directors of EQM's general partner or its conflicts committee, and assuming an agreement is reached, ETRN expects that the Proposed IDR Transaction would close in the first quarter of 2019. Upon completion of the Private Purchases, the Limited Call Right, and the Proposed IDR Transaction, ETRN will have accomplished a full simplification of EQGP and EQM, resulting in a projected 61% ownership of EQM. Additionally, EQM will be the only publicly traded partnership under ETRN and is expected to benefit from the elimination of the IDR burden, as well as stronger coverage and balance sheet metrics. Highlights: The proposed transactions would not result in a distribution cut for EQM unitholders; Targeting 6% - 8% annual distribution growth beginning in 2019; 2019 distribution coverage in excess of 1.0x; Long-term distribution coverage target in excess of 1.2x beginning in 2020; Long-term debt to EBITDA target of 3.5x - 4.0x beginning in 2020; PIK Units will provide balance sheet and coverage support; Improves cost of capital; No equity issuance is required to fund capital projects for the next several years; Reduces corporate overhead associated with the elimination of a publicly traded entity. ETRN expects that the EQM Conflicts Committee will review the Proposed IDR Transaction. Unitholder voting is not required in connection with the Private Purchases, the exercise of the Limited Call Right, or the Proposed IDR Transaction.

08:06 EDT Luby's says 'surprised' by Bandera Partners' nominations - Luby's confirmed that it has received notice on behalf of Bandera Partners and certain of its affiliates that it intends to nominate up to six candidates for election to Luby's Board of Directors at the 2019 Annual Meeting of Shareholders. Luby's issued the following statement: "Luby's Board is in the process of reviewing Bandera's nomination notice consistent with its fiduciary duties. The Luby's Board and management team are committed to acting in the best interests of the Company and its shareholders. We are always open to constructive ideas regardless of their source and will carefully consider Bandera's candidates as we would any other potential directors to assess their ability to add value to the Board for the benefit of all shareholders. Luby's notes that the Company was surprised by Bandera's nominations. Bandera approached the Company only a few days prior to the nomination deadline and demanded that the Board replace one third of the directors and appoint Jeff Gramm, his father Sen. Phil Gramm, and one of Bandera's close business associates to the Board. Even though the Board extended the nomination deadline to allow for constructive discussions, Bandera gave the Board only 48 hours to agree to their demands. The Company informed Bandera that 48 hours was an insufficient time for a public company board to commit to appointing three candidates whom the Board had not met and whose biographies they had not had an opportunity to carefully review and discuss. Christopher Pappas and Harris Pappas and the entire Board continue to support the Company's strategy and plans as have been previously disclosed. In furtherance of this support, each Luby's director has irrevocably committed to vote their shares in the Company in accordance with the recommendations of the Board at the 2019 Annual Meeting of Shareholders. The Board will review and consider Bandera's nomination notice and make a formal recommendation regarding director nominees in the Company's definitive proxy statement and other materials, to be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the 2019 Annual Meeting of Shareholders. Shareholders are not required to take any action at this time."

08:02 EDT Essendant, Staples announce extension of tender offer for Essendant shares - Staples and Essendant announced that, pursuant to the Merger Agreement, Egg Merger Sub and Egg Parent, affiliates of Staples, have extended the expiration time of the previously announced tender offer for all outstanding shares of Essendant's common stock to 6:00 p.m., New York City time, on December 4, 2018, unless the tender offer is further extended in accordance with the Agreement and Plan of Merger, dated as of September 14, 2018, by and among Essendant, Staples, Egg Parent and Egg Merger Sub. The tender offer was previously scheduled to expire at 6:00 p.m., New York City time, on November 29, 2018. The tender offer is being made pursuant to the Merger Agreement. Egg Merger Sub and Egg Parent expect the tender offer will be consummated promptly following the expiration time, subject to the satisfaction of the remaining closing conditions.

08:01 EDT General Dynamics European Land Systems acquires FWW Fahrzeugwerk GmbH - General Dynamics European Land Systems announced the acquisition of FWW Fahrzeugwerk GmbH, a qualified maintenance and service provider for the German Army and other international customers. FWW will become part of the newly-established General Dynamics European Land Systems - Deutschland, located in Berlin.

07:38 EDT Editas Medicine announces FDA acceptance of EDIT-101 IND, earns Allergan payment - Editas Medicine (EDIT) announced the FDA has accepted the company's investigational new drug, or IND, application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10, or LCA10. With the IND acceptance, Editas Medicine has earned a $25M milestone payment from Allergan (AGN) as part of the alliance between the companies to discover and develop experimental ocular medicines targeting serious, vision-threatening diseases. Editas Medicine and its partner, Allergan Pharmaceuticals International, a wholly-owned subsidiary of Allergan, expect to enroll 10 to 20 patients in a Phase 1/2 open label, dose escalation study to evaluate the safety, tolerability, and efficacy of EDIT-101.

07:35 EDT Neos Therapeutics CCO resigns, announces realignment of ADHD products - Neos Therapeutics announced that it completed a strategic assessment of its commercial business and is realigning its commercial organization for its attention deficit hyperactivity disorder, or ADHD, products Adzenys XR-ODT, Cotempla XR-ODT and Adzenys-ER in order to accelerate its path to profitability. In connection with this realignment, Neos also announced that its CCO, Thomas McDonnell, resigned upon mutual agreement with the company effective immediately. Additionally, the company has approved a plan to realign its sales force with the goal of better focusing on those territories and physician targets that have the highest potential to support the long-term growth and profitability of its ADHD business.

07:05 EDT LabCorp down about 5% after lowering FY18 guidance - In pre-market trading, shares are down 4.83% to $154.00.

07:02 EDT Trecora Resources CEO Simon Upfill-Brown to resign, Patrick Quarles to succeed - The Board of Directors of Trecora Resources (TREC) announced that Patrick Quarles has been appointed President and CEO. Quarles will be replacing Simon Upfill-Brown who has announced his plans to resign from the position to pursue other opportunities, effective Monday, December 3, 2018. Quarles will continue to serve as a member of the Board. Quarles joined Trecora's Board in September of this year, and he brings over 25 years of experience in the petrochemical industry. Most recently, Quarles served as Executive Vice President and President, Acetyl Chain and Global Supply Management at Celanese (CE).

07:00 EDT LabCorp cuts FY18 diagnostics revenue growth view to 2.1%-2.5% from 3%-3.5%

06:56 EDT LabCorp cuts FY18 outlook

06:46 EDT Citi Trends announces new $25M share repurchase program - During the third quarter, the company completed the $25M stock repurchase program that had been authorized by the company's Board of Directors on March 16, 2018. As the next step in the company's expanded capital return program announced in April 2017, the company's Board of Directors today announced the authorization of another $25M share repurchase program, which the company expects to fund from cash on hand.

06:28 EDT Marriott down 5.6% after announcing data breach

06:17 EDT Marriott data breach impacts 327M guests, includes address, passport number - Marriott says for approximately 327M of these guests, the information includes some combination of name, mailing address, phone number, email address, passport number, Starwood Preferred Guest account information, date of birth, gender, arrival and departure information, reservation date, and communication preferences.

06:08 EDT Callaway Golf to acquire Jack Wolfskin for approximately $476M - Callaway Golf announced that it has entered into an agreement to acquire Jack Wolfskin for approximately $476M, subject to certain purchase price adjustments. Jack Wolfskin is an outdoor apparel, footwear and equipment brand. The company designs products targeted at the active outdoor and urban outdoor customer categories. Jack Wolfskin had net sales of $380M in FY18, based on preliminary unaudited results provided by Jack Wolfskin. Jack Wolfskin provides over 3,000 points of sale globally, including wholesale, company-owned retail and franchised retail stores. Post transaction, Jack Wolfskin will continue to operate out of its headquarters located in Idstein, Germany. The $476M purchase price values Jack Wolfskin at a multiple of approximately 12 times its FY18 adjusted EBITDA of $40M. FY19 net sales are estimated to be flat compared to prior year, but are expected to accelerate to mid-single digit growth over the mid- to long-term. FY19 adjusted EBITDA, excluding purchase accounting adjustments, is estimated to be approximately $33M, a decrease compared to the prior year as a result of incremental investments to build long-term sustainable growth as well as projected cost of living increases. The investments would include investments in design, marketing and infrastructure to allow for growth in Jack Wolfskin's core business as well as future expansion into new regions. Jack Wolfskin's EBITDA is estimated to reach $50M in 3-4 years, with long-term EBITDA margins forecasted to be accretive to Callaway's current EBITDA margins. Full year non-GAAP EPS is estimated to be 6c dilutive in year one and accretive in year two. Non-GAAP EPS excludes non-recurring transaction costs, amortization of financing fees, and incremental non-cash expense resulting from the purchase accounting adjustments. Full year GAAP EPS is expected to be 25c-35c dilutive in year one and approximately neutral in year two. The acquisition is expected to close in the first quarter of 2019, subject to regulatory approvals and other customary closing conditions. Callaway intends to finance the transaction with a $476M term loan facility.

06:04 EDT Marriott announces Starwood guest reservation database security incident - Marriott has taken measures to investigate and address a data security incident involving the Starwood guest reservation database. On November 19, the investigation determined that there was unauthorized access to the database, which contained guest information relating to reservations at Starwood properties* on or before September 10. On September 8, Marriott received an alert from an internal security tool regarding an attempt to access the Starwood guest reservation database in the United States. Marriott quickly engaged leading security experts to help determine what occurred. Marriott learned during the investigation that there had been unauthorized access to the Starwood network since 2014. The company recently discovered that an unauthorized party had copied and encrypted information, and took steps towards removing it. On November 19, Marriott was able to decrypt the information and determined that the contents were from the Starwood guest reservation database. The company has not finished identifying duplicate information in the database, but believes it contains information on up to approximately 500 million guests who made a reservation at a Starwood property. For approximately 327M of these guests, the information includes some combination of name, mailing address, phone number, email address, passport number, Starwood Preferred Guest, or SPG, account information, date of birth, gender, arrival and departure information, reservation date, and communication preferences. For some, the information also includes payment card numbers and payment card expiration dates, but the payment card numbers were encrypted using Advanced Encryption Standard encryption, or AES-128. There are two components needed to decrypt the payment card numbers, and at this point, Marriott has not been able to rule out the possibility that both were taken. For the remaining guests, the information was limited to name and sometimes other data such as mailing address, email address, or other information. Marriott reported this incident to law enforcement and continues to support their investigation. The company has already begun notifying regulatory authorities. "We deeply regret this incident happened," said Arne Sorenson, Marriott's president and CEO. "We fell short of what our guests deserve and what we expect of ourselves. We are doing everything we can to support our guests, and using lessons learned to be better moving forward. Today, Marriott is reaffirming our commitment to our guests around the world. We are working hard to ensure our guests have answers to questions about their personal information, with a dedicated website and call center. We will also continue to support the efforts of law enforcement and to work with leading security experts to improve. Finally, we are devoting the resources necessary to phase out Starwood systems and accelerate the ongoing security enhancements to our network," Sorenson continued.

06:02 EDT Kirkland Lake Gold hikes Fosterville Mine production view to over 330,000 ounces - Kirkland Lake Gold announced that the company's Fosterville Mine is on track for record quarterly production in the fourth quarter of 2018, with full-year 2018 production now expected to exceed 330,000 ounces versus current guidance of 300,000 - 310,000 ounces. Fosterville's strong Q4 2018 performance largely reflects higher than expected grades and the advancement of two additional stopes from the high-grade Swan Zone into the mine's Q4 2018 production plan. Based on the improved outlook for Fosterville, the company now anticipates that full-year 2018 consolidated production will exceed the current target range of 655,000 - 670,000 ounces. On a quarter-to-date basis, the mill grade at Fosterville in Q4 2018 has averaged over 35.0 grams per tonne, well above target levels for the quarter. The outperformance largely relates to increased operating development activity around the Swan Zone and higher than planned grades from development tonnes processed. In addition, recent stope production from both the Swan and Eagle zones achieved substantially higher than expected grades. With increased operating development metres being completed, the Company has added two Swan Zone stopes to the mine plan for Q4 2018, which is also expected to contribute to increased levels of production.

05:31 EDT Himax chairman to purchase about $5M of shares - Himax Technologies announced that its chairman Dr. Biing-Seng Wu intends to use his personal funds to purchase up to approximately $5M of the company's American Depositary Shares in the open market, subject to market conditions and other factors. As of September 30, 2018, Dr. Biing-Seng Wu beneficially owns approximately 20.7% of the total outstanding shares of the company.

05:14 EDT Celyad doses first mCRC patient in Phase 1 alloSHRINK trial - Celyad announced the injection of the first patient in the Phase 1 alloSHRINK trial evaluating the company's non-gene edited allogeneic CAR-T therapy, CYAD-101, administered concurrently with FOLFOX chemotherapy in the treatment of patients with unresectable metastatic colorectal cancer.